• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Projected COVID-19 Mortality Reduction From Paxlovid Rollout.

作者信息

Khunte Mihir, Kumar Soryan, Salomon Joshua A, Bilinski Alyssa

机构信息

Warren Alpert Medical School, Brown University, Providence, Rhode Island.

Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, California.

出版信息

JAMA Health Forum. 2023 Mar 3;4(3):e230046. doi: 10.1001/jamahealthforum.2023.0046.

DOI:10.1001/jamahealthforum.2023.0046
PMID:36930169
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10024200/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5361/10024200/cc8711e31789/jamahealthforum-e230046-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5361/10024200/cc8711e31789/jamahealthforum-e230046-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5361/10024200/cc8711e31789/jamahealthforum-e230046-g001.jpg

相似文献

1
Projected COVID-19 Mortality Reduction From Paxlovid Rollout.预计帕罗韦德推出后可降低新冠病毒感染死亡率。
JAMA Health Forum. 2023 Mar 3;4(3):e230046. doi: 10.1001/jamahealthforum.2023.0046.
2
Paxlovid for treatment of COVID-19.用于治疗新冠病毒病的帕罗韦德
Med Lett Drugs Ther. 2022 Jan 24;64(1642):9-10.
3
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities.阿兹夫定与帕罗韦德用于合并基础疾病的中国新冠患者口服治疗的对比研究
J Infect. 2023 Aug;87(2):e24-e27. doi: 10.1016/j.jinf.2023.05.012. Epub 2023 May 17.
4
COVID drug Paxlovid was hailed as a game-changer. What happened?新冠药物帕罗韦德曾被誉为一项重大突破。后来发生了什么？
Nature. 2023 Jan;613(7943):224-225. doi: 10.1038/d41586-022-04576-6.
5
FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment.美国食品药品监督管理局（FDA）完全批准新冠病毒抗病毒治疗药物帕罗韦德（Paxlovid）。
JAMA. 2023 Jun 27;329(24):2118. doi: 10.1001/jama.2023.9925.
6
Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.三种新型口服抗病毒药物（莫努匹韦、氟伏沙明和帕罗韦德）治疗 COVID-19 的疗效和安全性：一项荟萃分析。
Ann Med. 2022 Dec;54(1):516-523. doi: 10.1080/07853890.2022.2034936.
7
From Positive to Negative to Positive Again-The Mystery of Why COVID-19 Rebounds in Some Patients Who Take Paxlovid.从阳性到阴性再到阳性——服用帕罗韦德的部分新冠患者病情反弹之谜
JAMA. 2022 Jun 28;327(24):2380-2382. doi: 10.1001/jama.2022.9925.
8
Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.社论：使用 Paxlovid 和 Molnupiravir 治疗 SARS-CoV-2 后新冠病毒反弹和抗病毒治疗停止。
Med Sci Monit. 2022 Oct 1;28:e938532. doi: 10.12659/MSM.938532.
9
Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.帕克洛维德药物说明书中列出的相互作用，根据风险、药物类别和后果进行分类。
Rev Esp Quimioter. 2022 Aug;35(4):357-361. doi: 10.37201/req/054.2022. Epub 2022 Jul 13.
10
Treatment of COVID-19 in high-risk outpatients.高危门诊患者的新冠病毒病治疗
Med Lett Drugs Ther. 2022 Feb 7;64(1643):e1.

引用本文的文献

1
Distal protein-protein interactions contribute to nirmatrelvir resistance.远端蛋白质-蛋白质相互作用导致对奈玛特韦耐药。
Nat Commun. 2025 Feb 1;16(1):1266. doi: 10.1038/s41467-025-56651-x.
2
The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo.SARS-CoV-2 3CL蛋白酶小分子抑制剂EDP-235可在体内阻止病毒复制和传播。
Nat Commun. 2024 Aug 1;15(1):6503. doi: 10.1038/s41467-024-50931-8.
3
A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy.

本文引用的文献

1
Covid-19: FDA authorises pharmacists to prescribe Paxlovid.新冠疫情：美国食品药品监督管理局授权药剂师开具帕罗韦德处方。
BMJ. 2022 Jul 8;378:o1695. doi: 10.1136/bmj.o1695.
2
Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease.SARS-CoV-2 主蛋白酶（Mpro）对蛋白酶抑制剂的潜在耐药性：从 HIV-1 蛋白酶中吸取的教训。
Int J Mol Sci. 2022 Mar 23;23(7):3507. doi: 10.3390/ijms23073507.
一种统一的模型来解释奈玛特韦治疗后 SARS-CoV-2 频繁反弹和有限的预防效果。
Nat Commun. 2024 Jun 28;15(1):5478. doi: 10.1038/s41467-024-49458-9.
4
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound.一个统一模型，用于解释尽管奈玛特韦暴露后预防效果不佳且病毒频繁反弹，但对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍具有较高治疗效果。
medRxiv. 2024 Apr 17:2023.08.23.23294505. doi: 10.1101/2023.08.23.23294505.
5
Have Diagnostics, Therapies, and Vaccines Made the Difference in the Pandemic Evolution of COVID-19 in Comparison with "Spanish Flu"?与“西班牙流感”相比，诊断方法、治疗手段和疫苗对新冠疫情演变产生了影响吗？
Pathogens. 2023 Jun 23;12(7):868. doi: 10.3390/pathogens12070868.